BiotechTube

5 mg Serlopitant Tablets

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis

Trial Timeline

Mar 15, 2018 → Jun 17, 2020

NCT ID
NCT03540160

About 5 mg Serlopitant Tablets

5 mg Serlopitant Tablets is a phase 3 stage product being developed by Vyne Therapeutics for Pruritus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03540160. Target conditions include Pruritus, Prurigo Nodularis, Atopic Dermatitis.

What happened to similar drugs?

0 of 5 similar drugs in Pruritus were approved

Approved (0) Terminated (0) Active (5)
🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3
🔄Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03540160Phase 3Terminated

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
32
SHR0410Jiangsu Hengrui MedicinePhase 1
29
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
25
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
35
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
40
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
35
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
47
BLU-5937 + PlaceboGSK plcPhase 2
35
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
35
REGN846Regeneron PharmaceuticalsPhase 1/2
24
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
35
HSK21542 tablet + PlaceboHaisco Pharmaceutical GroupPhase 2
31
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
32
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
32
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
25
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
19